1. Home
  2. TG vs IKT Comparison

TG vs IKT Comparison

Compare TG & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tredegar Corporation

TG

Tredegar Corporation

N/A

Current Price

$7.94

Market Cap

262.4M

Sector

Industrials

ML Signal

N/A

Logo Inhibikase Therapeutics Inc.

IKT

Inhibikase Therapeutics Inc.

N/A

Current Price

$2.50

Market Cap

220.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TG
IKT
Founded
1988
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Fabrications
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
262.4M
220.5M
IPO Year
1994
2020

Fundamental Metrics

Financial Performance
Metric
TG
IKT
Price
$7.94
$2.50
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$5.00
AVG Volume (30 Days)
172.2K
513.9K
Earning Date
05-08-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
151.06
57.76
EPS
0.34
N/A
Revenue
$800,821,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$23.44
N/A
Revenue Growth
8.29
N/A
52 Week Low
$6.25
$1.33
52 Week High
$10.53
$2.54

Technical Indicators

Market Signals
Indicator
TG
IKT
Relative Strength Index (RSI) 52.41 64.30
Support Level $7.29 $2.31
Resistance Level $8.20 $2.53
Average True Range (ATR) 0.38 0.10
MACD -0.01 -0.01
Stochastic Oscillator 22.60 89.13

Price Performance

Historical Comparison
TG
IKT

About TG Tredegar Corporation

Tredegar Corp is engaged in the manufacture of aluminum extrusions and polyethylene and polypropylene plastic films. It produces surface protection films, packaging films and films for other markets. The company continues to have two reportable segments: Aluminum Extrusions and High Performance Films. The majority of the revenue is derived form the Aluminum Extrusions segment which produces high-quality, soft and medium strength alloyed aluminum extrusions, custom fabricated and finished, for the building and construction, automotive and transportation, consumer durables goods, machinery and equipment, electrical and renewable energy, and distribution markets.

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.

Share on Social Networks: